Back to search

Peptide record

TPDB12942

Oligo10 Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB12942
Oligo10
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF Antifungipept CAFPdb dbAMP PD_Hemolysis DBAASP
standard
No
A 15-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
FAKALKALLKALKAL
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C78H139N19O16
RNDCEQGHIMPSTWYV
AL
1599.08
11.00
4
0
11
+4
-0.96
1.013
163.33
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
5
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
5
L
4
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 5 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 5 K: 4 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
15 reviewed residue count
C78H139N19O16 sequence-only estimate (linear, free termini)
1599.08 sequence-only estimate (linear, free termini)
11.00 sequence-only estimate (linear, free termini)
+4 sequence-only estimate (linear, free termini)
-0.96 sequence-only estimate (linear, free termini)
1.013 sequence-only estimate (linear, free termini)
Evidence Records 19 records
Evidence 1 Activity

Activity

MIC
Antibacterial
16.0 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/m
Evidence 2 Activity

Activity

MIC
Antibacterial
63.0 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP

Other

Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), a
Evidence 3 Activity

Activity

MIC
Antibacterial
63.0 µg/mL

Target

K. pneumonia

Source & Reference

dbAMP

Other

Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 4 Activity

Activity

MIC
Antibacterial
16.0 µg/mL

Target

E. faecium

Source & Reference

dbAMP

Other

E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 5 Activity

Activity

MIC
Antibacterial
4.0 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP

Other

aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 6 Activity

Activity

MIC
Antibacterial
2.0 µg/mL

Target

C. acnes

Source & Reference

dbAMP

Other

. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 7 Activity

Activity

MIC
Antifungal
16.0 µg/mL

Target

Escherichia coli

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/m
Evidence 8 Activity

Activity

MIC
Antifungal
63.0 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), a
Evidence 9 Activity

Activity

MIC
Antifungal
63.0 µg/mL

Target

K. pneumonia

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 10 Activity

Activity

MIC
Antifungal
16.0 µg/mL

Target

E. faecium

Source & Reference

dbAMP CAFPdb Antifungipept

Other

E. coli (MIC 16.0 ug/ml), P. aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 11 Activity

Activity

MIC
Antifungal
4.0 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP CAFPdb Antifungipept

Other

aeruginosa (MIC 63.0 ug/ml), K. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 12 Activity

Activity

MIC
Antifungal
2.0 µg/mL

Target

C. acnes

Source & Reference

dbAMP CAFPdb Antifungipept

Other

. pneumonia (MIC 63.0 ug/ml), E. faecium (MIC 16.0 ug/ml), S. aureus (MIC 4.0 ug/ml), and C. acnes (MIC 2.0 ug/ml).
Evidence 13 Activity

Activity

LD50
Toxicity
37 µg/mL
Cytotoxic
LD50 | 37 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 14 Activity

Activity

50% Hemolysis
Toxicity
6 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 6 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 15 Activity

Activity

IC50
Toxicity
218.21 µg/mL
Cytotoxic
IC50 | 218.21 | µg/mL | target cell: Mouse fibroblasts BALB/3T3

Target

Mouse fibroblasts BALB/3T3

Source & Reference

NA
DBAASP
Comparative Evaluation of Existing and Rationally Designed Novel Antimicrobial Peptides for Treatment of Skin and Soft Tissue Infections. | J Antibiot (Tokyo) | 2023
Evidence 16 Activity

Activity

IC50
Toxicity
241.54 µg/mL
Cytotoxic
IC50 | 241.54 | µg/mL | target cell: Human dermal fibroblasts

Target

Human dermal fibroblasts

Source & Reference

NA
DBAASP
Comparative Evaluation of Existing and Rationally Designed Novel Antimicrobial Peptides for Treatment of Skin and Soft Tissue Infections. | J Antibiot (Tokyo) | 2023
Evidence 17 Activity

Activity

18% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
18% Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Comparative Evaluation of Existing and Rationally Designed Novel Antimicrobial Peptides for Treatment of Skin and Soft Tissue Infections. | J Antibiot (Tokyo) | 2023
Evidence 18 Activity

Target

Cutibacterium acnes

Source & Reference

DBAASP
Evidence 19 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis